查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1504207

临床试验的市场规模，占有率，预测，趋势分析:各类服务，各治疗领域，不同阶段，各终端用户-2031年前的全球预测

Clinical Trials Market Size, Share, Forecast, & Trends Analysis by Service Therapeutic Area Phase, End User - Global Forecast to 2031
出版日期: | 出版商: Meticulous Research | 英文 230 Pages | 商品交期: 5-7个工作天内

价格

到2031年，临床试验市场预计将达到1022亿美元，2024年至2031年的复合年增长率为7.2%。

本报告在对市场情景进行广泛的二次研究、初步研究和详细分析后，对主要行业促进因素、市场限制因素、市场促进因素和课题进行了分析。临床试验市场的成长是由对罕见疾病的日益关注、个人化医疗的日益采用、研发成本的上升以及透过改进临床试验招募流程提高参与者保留率所推动的。然而，更长的临床试验持续时间、更严格的法规以及不断变化的法律增加了临床试验的复杂性，正在限制该市场的成长。

此外，利用医疗物联网 (IoMT)、基于云端的药物警戒系统以及将人工智慧整合到临床试验中的以患者为中心的临床试验的进展预计将为市场利益相关者提供成长机会。然而，缺乏熟练和专业的公司进行临床试验、临床试验方案的复杂性以及缺乏多种族的参与是临床试验市场的主要课题。我们还将数位健康技术引入临床试验，在临床试验中使用可穿戴技术、临床试验自动化、临床试验分散化、用于患者丰富和招募的AI建模和预测以及使用AI分析的临床试验等都是值得注意的。

目录

第1章 简介

第2章 调查手法

第3章 摘要整理

第 4 章市场洞察

  • 摘要
  • 促进因素
    • 越来越关注罕见疾病
    • 越来越多采用个人化医疗
    • 研发费用增加
    • 透过改善临床试验的招募流程来确保参与者的安全
  • 抑制因素
    • 临床试验过程漫长
    • 由于严格的法规和法律变化，临床试验变得更加复杂
  • 机会
    • 利用医疗物联网 (IoMT) 进行以病人为中心的临床试验
    • 基于云端的药物警戒系统的进展
    • 将人工智慧融入临床试验地点选择
  • 作业
    • 缺乏熟练的临床试验专家
    • 临床试验方案的复杂性
    • 缺乏多族群的参与
  • 趋势
    • 将数位健康技术引入临床试验
    • 穿戴式科技在临床试验的应用
    • 临床试验自动化
    • 临床试验的分散化
    • 患者丰富和招募的人工智慧建模和预测
    • 使用人工智慧进行临床试验分析
  • 因素分析
  • 监理分析
    • 美国
    • 加拿大
    • 欧洲
    • 中国
    • 日本
    • 印度
    • 拉丁美洲
    • 中东
  • 个案研究
  • 波特五力分析

第五章临床试验市场：分阶段评估

  • 摘要
  • 临床前研究
  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 第四阶段

第六章临床试验市场：依服务类型评估

  • 服务概览
  • 咨询服务
  • 安全与监理合规服务
  • 设施/病患支援服务
  • 行销审批相关服务
  • 资料管理服务
  • 分散临床试验 (DCT)/虚拟临床试验 (VCT) 服务
  • 病患招募服务
  • 统计分析服务
  • 生物分析服务
  • 其他服务

第七章临床试验市场：依治疗领域评估

  • 摘要
  • 癌症领域
  • 传染病
  • 循环系统
  • 新陈代谢/内分泌
  • 中枢神经系统 (CNS)/神经病学
  • 皮肤科
  • 骨科/风湿科
  • 罕见疾病
  • 胃肠病学/肝病学
  • 呼吸系统
  • 女性健康
  • 泌尿科
  • 心理健康
  • 眼科

第8章 临床试验市场:各终端用户评估

  • 概要
  • 医药品·生物科技企业
  • 医疗设备企业
  • 其他的终端用户

第9章 临床试验市场:各终端用户评估

  • 概要
  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 波兰
    • 比利时
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 其他亚太地区
  • 南美
    • 巴西
    • 墨西哥
    • 其他南美国家
  • 中东·非洲

第10章 竞争分析

  • 概要
  • 主要成长策略
  • 竞争基准
  • 竞争仪表板
    • 产业领导者
    • 市场差异化要素
    • 领先企业
    • 新兴企业
  • 主要企业的市场占有率分析/市场排行榜(2023年)

第11章 企业简介(产业概要，财务概要，产品系列，策略性展开，SWOT分析*)

  • Laboratory Corporation of America Holdings
  • Medpace, Inc.
  • Charles River Laboratories International, Inc.
  • IQVIA Inc.
  • Parexel International Corporation
  • Syneos Health
  • ICON plc
  • WuXi AppTec Co., Ltd.
  • Thermo Fisher Scientific Inc.
  • Fortrea Inc.
  • Celerion Inc.
  • Novotech Health Holdings
  • SGS Societe Generale de Surveillance SA.
  • CTI Clinical Trial and Consulting, Inc.
  • Linical USA, Inc.

(註：提供前 5 名公司 SWOT 分析)

第12章 附录

Product Code: MRHC - 1041251

Clinical Trials Market Size, Share, Forecast, & Trends Analysis by Service (Consulting, Patient Recruitment, Data Management, Regulatory, Site Support), Therapeutic Area (Oncology, Cardiology, Diabetes, Dermatology), Phase, End User-Global Forecast to 2031

The clinical trials market is projected to reach $102.20 billion by 2031, at a CAGR of 7.2% from 2024 to 2031.

After extensive secondary and primary research and an in-depth analysis of the market scenario, the report provides an analysis of key industry drivers, restraints, opportunities, and challenges. The growth of the clinical trials market is driven by the increasing focus on rare diseases, the rising adoption of personalized medicine, increasing research & development expenditures, and improvements in the clinical trials recruitment process resulting in improved participant retention. However, the extended durations of clinical trials, stringent regulations, and changing laws increasing the complexity of clinical trials restrain the growth of this market.

Furthermore, patient-centric clinical trials using the Internet of Medical Things (IoMT), advancements in cloud-based systems for pharmacovigilance, and the integration of AI into clinical trials are expected to offer growth opportunities for market stakeholders. However, the lack of skilled professionals to conduct clinical trials, the complexity of clinical trial protocols, and the lack of participation from several ethnic groups are major challenges in the clinical trials market. Also, the incorporation of digital health technologies into clinical trials, the use of wearable technologies for clinical trials, automation of clinical trials, decentralized clinical trials, AI modeling and forecasting of patient enrichment and recruitment, and AI-enabled clinical trial analytics are prominent trends in the clinical trials market.

The report offers a competitive landscape based on an extensive assessment of the leading players' product portfolios, geographic presence, and key strategies adopted over the last four years (2020-2024). The key players operating in the clinical trials market are Laboratory Corporation of America Holdings (U.S.), Medpace, Inc. (U.S.), Charles River Laboratories International, Inc. (U.S.), IQVIA Inc. (U.S.), Parexel International Corporation (U.S.), Syneos Health (U.S.), ICON plc (Ireland), WuXi AppTec Co., Ltd. (China), Thermo Fisher Scientific Inc. (U.S.), Fortrea Inc. (U.S.), Celerion Inc. (U.S.), Novotech Health Holdings (Australia), SGS Societe Generale de Surveillance SA. (Switzerland), CTI Clinical Trial and Consulting, Inc. (U.S.), and Linical USA, Inc. (U.S.).

Based on phase, the clinical trials market is segmented into pre-clinical trials, phase I, phase II, phase III, and phase IV. In 2024, the phase III segment is expected to account for the largest share of 68.4% of the clinical trials market. Phase III clinical trials use large groups of people to observe the adverse effects of treatments and utilize sophisticated services for studying the efficacy and safety of drugs. Such factors have contributed to the largest share of this segment. Additionally, many pharmaceutical and biotechnology companies outsource their phase III clinical trials to service providers, supporting the segment's large share.

Among all the therapeutic areas studied in this report, in 2024, the oncology segment is expected to account for the largest share of the clinical trials market. The largest share of this segment is attributed to the high prevalence of cancer, government support to develop new cancer medicines, high healthcare expenditure for cancer, and an increasing number of clinical trials in oncology. For instance, according to a November 2023 report by Pharmaceutical Research and Manufacturers of America (U.S.), 1,600 treatments and vaccines are in development for cancer. Such developments are expected to support the segment's large share.

Among all the end users studied in this report, in 2024, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the clinical trials market. The segment's large share is attributed to the increasing demand for innovative therapies for various diseases. Pharmaceutical & biotechnology companies' high investments in R&D for the development of new drugs and therapies are driving clinical trials, contributing to the segment's large share.

An in-depth analysis of the geographical scenario in the clinical trials market provides detailed qualitative and quantitative insights into five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is expected to account for the largest share of 41.6% of the clinical trials market. North America's significant market share is attributed to increasing R&D investments, the rising adoption of new technologies in clinical trials, and the presence of key market players in this region. For instance, in March 2024, the Laboratory Corporation of America Holdings (U.S.) launched pTau217, a biomarker test for accelerating the diagnosis of Alzheimer's disease, which is also used for clinical trials. Additionally, according to the National Library of Medicine (U.S.), approximately 149,999 clinical trial studies were registered in the U.S. as of April 2024.

Scope of the Report:

Clinical Trials Market Assessment-by Phase

  • Pre-clinical Trial
  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Clinical Trials Market Assessment-by Service Type

  • Consulting Services
  • Safety & Regulatory Compliance Services
  • Site & Patient Support Services
  • Marketing Authorization Holder Related Services
  • Data Management Services
  • Decentralized Clinical Trials (DCT)/Virtual Clinical Trials (VCT) Services
  • Patient Recruitment Services
  • Statistical Analysis Services
  • Bioanalytical services
  • Other Services

Note: Other services include sample storage & aliquoting services, laboratory services, research review services, manufacturing services, cold chain logistics & management services, and In-Country Clinical Caretaker (ICCC) Services.

Clinical Trials Market Assessment-by Therapeutic Area

  • Oncology
  • Infectious Diseases
  • Cardiology
  • Metabolism & Endocrinology
  • Central Nervous System (CNS)/Neurology
  • Dermatology
  • Orthopedic & Rheumatology
  • Rare Diseases
  • Gastroenterology & Hepatology
  • Respiratory
  • Women's Health
  • Urology
  • Mental Health
  • Ophthalmology

Clinical Trials Market Assessment-by End User

  • Pharmaceutical & Biotechnology Companies
  • Medical Device Companies
  • Other End Users

Note: Other end users include Contract Research Organizations (CROs), academic & research institutions, and government organizations.

Clinical Trials Market Assessment-by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K
    • Italy
    • Spain
    • Poland
    • Belgium
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition & Scope
  • 1.2. Market Ecosystem
  • 1.3. Currency and Limitations
  • 1.4. Key Stakeholders

2. Research Methodology

  • 2.1. Research Approach
  • 2.2. Process of Data Collection & Validation
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
  • 2.3. Market Sizing and Forecasting
    • 2.3.1. Market Size Estimation Approach
    • 2.3.2. Growth Forecast Approach
    • 2.3.3. Market Share Analysis
  • 2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights

  • 4.1. Overview
  • 4.2. Drivers
    • 4.2.1. Increasing Focus on Rare Diseases
    • 4.2.2. Rise in Adoption of Personalized Medicine
    • 4.2.3. Increasing Research and Development Expenditure
    • 4.2.4. Improvement in Recruitment Process in Clinical Trials Resulting in Retention of Participants
  • 4.3. Restraints
    • 4.3.1. The Time-consuming Process of Clinical Trials
    • 4.3.2. Stringent Regulations and Changing Laws Increasing the Complexity of Clinical Trials
  • 4.4. Opportunities
    • 4.4.1. Patient-centric Clinical Trials Using Internet of Medical Things (IoMT)
    • 4.4.2. Advancements in Cloud-based Systems for Pharmacovigilance
    • 4.2.3. Integration of AI in Clinical Trial Site Selection
  • 4.5. Challenges
    • 4.5.1. Lack of Skilled Professionals in Clinical Trial
    • 4.5.2. Complexity in Clinical Trial Protocols
    • 4.5.3. Lack of Participation from Several Ethnic Groups
  • 4.6. Trends
    • 4.6.1. Incorporating Digital Health Technologies into Clinical Trial
    • 4.6.2. Use of Wearable Technology for Clinical Trials
    • 4.6.3. Automated Clinical Trials
    • 4.6.4. Decentralized Clinical Trials
    • 4.6.5. AI Modeling and Forecasting Patient Enrichment & Recruitment
    • 4.6.6. AI-enabled Clinical Trial Analytics
  • 4.7. Factor Analysis
  • 4.8. Regulatory Analysis
    • 4.8.1. U.S.
    • 4.8.2. Canada
    • 4.8.3. Europe
    • 4.8.4. China
    • 4.8.5. Japan
    • 4.8.6. India
    • 4.8.7. Latin America
    • 4.8.8. Middle East
  • 4.9. Case Studies
  • 4.10. Porter's Five Forces Analysis

5. Clinical Trials Market Assessment-by Phase

  • 5.1. Overview
  • 5.2. Pre-clinical Trial
  • 5.3. Phase I
  • 5.4. Phase II
  • 5.5. Phase III
  • 5.6. Phase IV

6. Clinical Trials Market Assessment-by Service Type

  • 6.1. Overview
  • 6.2. Consulting Services
  • 6.3. Safety & Regulatory Compliance Services
  • 6.4. Site & Patient Support Services
  • 6.5. Marketing Authorization Holder Related Services
  • 6.6. Data Management Services
  • 6.7. Decentralized Clinical Trials (DCT)/Virtual Clinical Trials (VCT) Services
  • 6.8. Patient Recruitment Services
  • 6.9. Statistical Analysis Services
  • 6.10. Bioanalytical Services
  • 6.11. Other Services

7. Clinical Trials Market Assessment-by Therapeutic Area

  • 7.1. Overview
  • 7.2. Oncology
  • 7.3. Infectious Diseases
  • 7.4. Cardiology
  • 7.5. Metabolism & Endocrinology
  • 7.6. Central Nervous System (CNS)/Neurology
  • 7.7. Dermatology
  • 7.8. Orthopedic and Rheumatology
  • 7.9. Rare Diseases
  • 7.10. Gastroenterology & Hepatology
  • 7.11. Respiratory
  • 7.12. Women's Health
  • 7.13. Urology
  • 7.14. Mental Health
  • 7.15. Ophthalmology

8. Clinical Trials Market Assessment-by End User

  • 8.1. Overview
  • 8.2. Pharmaceuticals & Biotechnology Companies
  • 8.3. Medical Device Companies
  • 8.4. Other End Users

9. Clinical Trials Market Assessment-by End User

  • 9.1. Overview
  • 9.2. North America
    • 9.2.1. U.S.
    • 9.2.2. Canada
  • 9.3. Europe
    • 9.3.1. Germany
    • 9.3.2. France
    • 9.3.3. U.K.
    • 9.3.4. Italy
    • 9.3.5. Spain
    • 9.3.6. Poland
    • 9.3.7. Belgium
    • 9.3.8. Rest of Europe
  • 9.4. Asia-Pacific
    • 9.4.1. Japan
    • 9.4.2. China
    • 9.4.3. India
    • 9.4.4. Australia
    • 9.4.5. South Korea
    • 9.4.6. Rest of Asia-Pacific
  • 9.5. Latin America
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America
  • 9.6. Middle East & Africa

10. Competition Analysis

  • 10.1. Overview
  • 10.2. Key Growth Strategies
  • 10.3. Competitive Benchmarking
  • 10.4. Competitive Dashboard
    • 10.4.1. Industry Leaders
    • 10.4.2. Market Differentiators
    • 10.4.3. Vanguards
    • 10.4.4. Emerging Companies
  • 10.5. Market Share Analysis/Market Rankings of Key Players (2023)

11. Company Profiles (Business Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis*)

  • 11.1. Laboratory Corporation of America Holdings
  • 11.2. Medpace, Inc.
  • 11.3. Charles River Laboratories International, Inc.
  • 11.4. IQVIA Inc.
  • 11.5. Parexel International Corporation
  • 11.6. Syneos Health
  • 11.7. ICON plc
  • 11.8. WuXi AppTec Co., Ltd.
  • 11.9. Thermo Fisher Scientific Inc.
  • 11.10. Fortrea Inc.
  • 11.11. Celerion Inc.
  • 11.12. Novotech Health Holdings
  • 11.13. SGS Societe Generale de Surveillance SA.
  • 11.14. CTI Clinical Trial and Consulting, Inc.
  • 11.15. Linical USA, Inc.

(Note: SWOT analyses of the top 5 companies will be provided.)

12. Appendix

  • 12.1. Available Customization
  • 12.2. Related Reports

LIST OF TABLES

  • Table 1 Global Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 2 Global Pre-clinical Trial Market, by Country/Region, 2022-2031 (USD Million)
  • Table 3 Global Phase I Clinical Trials Market, by Country/Region, 2022-2031 (USD Million)
  • Table 4 Global Phase II Clinical Trials Market, by Country/Region, 2022-2031 (USD Million)
  • Table 5 Global Phase III Clinical Trials Market, by Country/Region, 2022-2031 (USD Million)
  • Table 6 Global Phase IV Clinical Trials Market, by Country/Region, 2022-2031 (USD Million)
  • Table 7 Global Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 8 Global Clinical Trials Consulting Services Market, by Country/Region, 2022-2031 (USD Million)
  • Table 9 Global Clinical Trials Safety & Regulatory Compliance Services Market, by Country/Region, 2022-2031 (USD Million)
  • Table 10 Global Clinical Trials Site & Patient Support Services Market, by Country/Region, 2022-2031 (USD Million)
  • Table 11 Global Clinical Trials Marketing Authorization Holder Related Services Market, by Country/Region, 2022-2031 (USD Million)
  • Table 12 Global Clinical Trials Data Management Services Market, by Country/Region, 2022-2031 (USD Million)
  • Table 13 Global Decentralized Clinical Trials (DCT) / Virtual Clinical Trials (VCT) Services Market, by Country/Region, 2022-2031 (USD Million)
  • Table 14 Global Clinical Trials Patient Recruitment Services Market, by Country/Region, 2022-2031 (USD Million)
  • Table 15 Global Clinical Trials Statistical Analysis Services Market, by Country/Region, 2022-2031 (USD Million)
  • Table 16 Global Clinical Trials Bioanalytical Services Market, by Country/Region, 2022-2031 (USD Million)
  • Table 17 Global Other Clinical Trials Services Market, by Country/Region, 2022-2031 (USD Million)
  • Table 18 Global Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 19 Global Clinical Trials Market for Oncology, by Country/Region, 2022-2031 (USD Million)
  • Table 20 Global Clinical Trials Market for Infectious Diseases, by Country/Region, 2022-2031 (USD Million)
  • Table 21 Global Clinical Trials Market for Cardiology, by Country/Region, 2022-2031 (USD Million)
  • Table 22 Global Clinical Trials Market for Metabolism & Endocrinology, by Country/Region, 2022-2031 (USD Million)
  • Table 23 Global Clinical Trials Market for Central Nervous System (CNS)/Neurology, by Country/Region, 2022-2031 (USD Million)
  • Table 24 Global Clinical Trials Market for Dermatology, by Country/Region, 2022-2031 (USD Million)
  • Table 25 Global Clinical Trials Market for Orthopedic and Rheumatology, by Country/Region, 2022-2031 (USD Million)
  • Table 26 Global Clinical Trials Market for Rare Diseases, by Country/Region, 2022-2031 (USD Million)
  • Table 27 Global Clinical Trials Market for Gastroenterology & Hepatology, by Country/Region, 2022-2031 (USD Million)
  • Table 28 Global Clinical Trials Market for Respiratory, by Country/Region, 2022-2031 (USD Million)
  • Table 29 Global Clinical Trials Market for Women's Health, by Country/Region, 2022-2031 (USD Million)
  • Table 30 Global Clinical Trials Market for Urology, by Country/Region, 2022-2031 (USD Million)
  • Table 31 Global Clinical Trials Market for Mental Health, by Country/Region, 2022-2031 (USD Million)
  • Table 32 Global Clinical Trials Market for Ophthalmology, by Country/Region, 2022-2031 (USD Million)
  • Table 33 Global Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 34 Global Clinical Trials Market for Pharmaceuticals & Biotechnology Companies, by Country/Region, 2022-2031 (USD Million)
  • Table 35 Global Clinical Trials Market for Medical Device Companies, by Country/Region, 2022-2031 (USD Million)
  • Table 36 Global Clinical Trials Market for Other End Users, by Country/Region, 2022-2031 (USD Million)
  • Table 37 Global Clinical Trials Market, by Country/Region, 2022-2031 (USD Million)
  • Table 38 North America: Clinical Trials Market, by Country, 2022-2031 (USD Million)
  • Table 39 North America: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 40 North America: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 41 North America: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 42 North America: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 43 U.S.: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 44 U.S.: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 45 U.S.: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 46 U.S.: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 47 Canada: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 48 Canada: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 49 Canada: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 50 Canada: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 51 Europe: Clinical Trials Market, by Country/Region, 2022-2031 (USD Million)
  • Table 52 Europe: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 53 Europe: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 54 Europe: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 55 Europe: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 56 Germany: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 57 Germany: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 58 Germany: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 59 Germany: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 60 France: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 61 France: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 62 France: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 63 France: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 64 U.K.: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 65 U.K.: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 66 U.K.: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 67 U.K.: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 68 Italy: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 69 Italy: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 70 Italy: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 71 Italy: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 72 Spain: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 73 Spain: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 74 Spain: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 75 Spain: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 76 Poland: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 77 Poland: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 78 Poland: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 79 Poland: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 80 Belgium: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 81 Belgium: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 82 Belgium: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 83 Belgium: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 84 Rest of Europe: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 85 Rest of Europe: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 86 Rest of Europe: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 87 Rest of Europe: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 88 Asia-Pacific: Clinical Trials Market, by Country/Region, 2022-2031 (USD Million)
  • Table 89 Asia-Pacific: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 90 Asia-Pacific: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 91 Asia-Pacific: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 92 Asia-Pacific: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 93 Japan: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 94 Japan: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 95 Japan: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 96 Japan: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 97 China: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 98 China: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 99 China: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 100 China: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 101 India: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 102 India: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 103 India: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 104 India: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 105 Australia: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 106 Australia: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 107 Australia: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 108 Australia: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 109 South Korea: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 110 South Korea: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 111 South Korea: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 112 South Korea: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 113 Rest of Asia-Pacific: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 114 Rest of Asia-Pacific: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 115 Rest of Asia-Pacific: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 116 Rest of Asia-Pacific: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 117 Latin America: Clinical Trials Market, by Country/Region, 2022-2031 (USD Million)
  • Table 118 Latin America: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 119 Latin America: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 120 Latin America: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 121 Latin America: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 122 Brazil: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 123 Brazil: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 124 Brazil: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 125 Brazil: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 126 Mexico: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 127 Mexico: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 128 Mexico: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 129 Mexico: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 130 Rest of Latin America: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 131 Rest of Latin America: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 132 Rest of Latin America: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 133 Rest of Latin America: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 134 Middle East & Africa: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 135 Middle East & Africa: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 136 Middle East & Africa: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 137 Middle East & Africa: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 138 Recent Developments, by Company, 2021-2024

LIST OF FIGURES

  • Figure 1 Research Process
  • Figure 2 Key Secondary Sources
  • Figure 3 Primary Research Techniques
  • Figure 4 Key Executives Interviewed
  • Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
  • Figure 6 Market Size Estimation
  • Figure 7 Global Clinical Trials Market, by Phase, 2024 VS. 2031 (USD Million)
  • Figure 8 Global Clinical Trials Market, by Service Type, 2024 VS. 2031 (USD Million)
  • Figure 9 Global Clinical Trials Market, by Therapeutic Area, 2024 VS. 2031 (USD Million)
  • Figure 10 Global Clinical Trials Market, by End User, 2024 VS. 2031 (USD Million)
  • Figure 11 Global Clinical Trials Market, by Geography
  • Figure 12 Impact Analysis: Clinical Trials Market
  • Figure 13 Global Clinical Trials Market, by Phase, 2024 VS. 2031 (USD Million)
  • Figure 14 Global Clinical Trials Market, by Service Type, 2024 VS. 2031 (USD Million)
  • Figure 15 Global Clinical Trials Market, by Therapeutic Area, 2024 VS. 2031 (USD Million)
  • Figure 16 Global Clinical Trials Market, by End User, 2024 VS. 2031 (USD Million)
  • Figure 17 Global Clinical Trials Market, by Geography, 2024 VS. 2031 (USD Million)
  • Figure 18 North America: Clinical Trials Market Snapshot
  • Figure 19 Europe: Clinical Trials Market Snapshot
  • Figure 20 Asia-Pacific: Clinical Trials Market Snapshot
  • Figure 21 Latin America: Clinical Trials Market Snapshot
  • Figure 22 Key Growth Strategies Adopted by Leading Players, 2021-2024
  • Figure 23 Global Clinical Trials Market: Competitive Benchmarking, by Service Type
  • Figure 24 Global Clinical Trials Market: Competitive Benchmarking, by Geography
  • Figure 25 Global Clinical Trials Market: Competitive Dashboard
  • Figure 26 Global Clinical Trials Market: Market Share Analysis/ Market Ranking, By Players (2023)
  • Figure 27 Laboratory Corporation of America Holdings: Financial Overview (2023)
  • Figure 28 Medpace, Inc.: Financial Overview (2023)
  • Figure 29 Charles River Laboratories International, Inc.: Financial Overview (2023)
  • Figure 30 IQVIA Inc.: Financial Overview (2023)
  • Figure 31 WuXi AppTec Co., Ltd.: Financial Overview (2023)
  • Figure 32 Thermo Fisher Scientific Inc.: Financial Overview (2023)
  • Figure 33 Fortrea Inc.: Financial Overview (2022)
  • Figure 34 Linical USA, Inc.: Financial Overview (2023)